Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/30/2025 | $20.00 | Buy | Alliance Global Partners |
| 6/26/2025 | $21.00 | Buy | B. Riley Securities |
| 5/20/2025 | $31.00 | Buy | Roth Capital |
| 10/21/2024 | $35.00 | Overweight | Piper Sandler |
| 5/17/2024 | $14.00 | Outperform | Oppenheimer |
| 1/5/2024 | $8.00 | Overweight | Cantor Fitzgerald |
| 10/26/2022 | $15.00 | Buy | Ladenburg Thalmann |
| 1/31/2022 | $14.00 → $18.00 | Buy | HC Wainwright & Co. |
SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 8, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expecte
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in DuchenneDeramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experienceCompany plans to submit i
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
Alliance Global Partners initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $20.00
B. Riley Securities initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $21.00
Roth Capital initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $31.00
424B5 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
424B3 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in DuchenneDeramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experienceCompany plans to submit i
Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with StealthX™ exosome-based vaccine; initial topline data currently expected in the first quarter of 2026, subject to completion by NIAIDCash balance of approximately $99 million expected to support planned oper
SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on the same day. Title:Capricor Therapeutics Third Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Monday, November 10, 2025Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)